Medical Condition News

RSS

MSU receives $6.2 million Morris K. Udall Center of Excellence for Parkinson's disease grant

A team of researchers from Michigan State University and the University of Cincinnati have been awarded a $6.2 million Morris K. Udall Center of Excellence for Parkinson's disease grant.

15 Oct 2009

Gelotophobia has no cultural barriers

Laughter is an emotional expression that is innate in human beings. This means laughing at others is also believed to be a universal phenomenon. However, the fear of being laughed at causes some people enormous problems in their social lives. This is known as gelotophobia, a disorder that affects people in all cultures alike.

15 Oct 2009

Foundation for Chiropractic Progress joins 92 national associations in support of World Spine Day

The Foundation for Chiropractic Progress (www.f4cp.com), a not-for-profit organization dedicated to increasing public awareness of the benefits of chiropractic, joins the 92 national associations that are currently members of the World Federation of Chiropractic in support of World Spine Day taking place on October 16, 2009.

15 Oct 2009

Diet and exercise program unlikely to eliminate OSA in overweight patients

A study in the Oct. 15 issue of the Journal of Clinical Sleep Medicine found that while a strict diet and exercise program may benefit obese patients with mild to moderate obstructive sleep apnea (OSA), it is unlikely to eliminate the condition.

15 Oct 2009

Shortage of general surgeons may be linked to higher rate of perforated appendix in rural areas

People who live in rural areas may run a greater risk of having perforated appendix than those in suburban and urban areas, according to a new study out of Dartmouth Medical School, Lebanon, NH. Not having enough general surgeons in rural regions may explain the disparity, according to researchers who presented their findings at the 95th annual Clinical Congress of the American College of Surgeons.

15 Oct 2009

Marker genes help determine the effectiveness of targeted molecular drug regimen for treating GIST

Analysis of a small number of marker genes may determine in a matter of hours if a patient with gastrointestinal stromal tumors (GIST) would respond to a targeted molecular drug regimen. This analysis could allow clinicians to determine if they have chosen the best course of action or need to consider another alternative.

15 Oct 2009

NYU Langone Medical Center to establish a schizophrenia research center with $10M NIMH grant

NYU Langone Medical Center has received a five-year, $10 million grant from the National Institute of Mental Health (NIMH) to establish a Silvio O. Conte Center for the Neuroscience of Mental Disorders. The center, named after the late Silvio O. Conte, a U.S. congressman and advocate for mental health research, will study the onset of schizophrenia. Schizophrenia is a disease with cognitive dysfunction, affecting approximately one percent of the population worldwide.

15 Oct 2009

Much remains to be done for autism spectrum disorders, say experts

Scientific understanding and medical treatments for autism spectrum disorders (ASDs) have advanced significantly over the past several years, but much remains to be done, say experts from the Center for Autism Research at The Children's Hospital of Philadelphia who published a scientific review of the field today.

15 Oct 2009

Genetic mutation implicated in breast and ovarian cancers could also have a role in causing heart failure: Study

A genetic mutation implicated in breast and ovarian cancers could also have a role in causing heart failure, according to a new study reported at the 95th annual Clinical Congress of the American College of Surgeons.

15 Oct 2009

Curemark commences enrollment in Phase III CM-AT clinical trials for autism treatment

Curemark, LLC, a drug research and development company focused on the treatment of neurological diseases, announced that it has enrolled the first patients in Phase III clinical trials for its autism treatment, CM-AT. The first clinical trial patients have been enrolled at Lake Mary Pediatrics in Orange City, Florida, one of 12 clinical trial sites with a total 170 children across the country.

15 Oct 2009

Control and coordination may aid multiple sclerosis patients perform daily activities independently

While gripping, lifting or manipulating an object such as drinking from a cup or placing a book on a shelf is usually easy for most, it can be challenging for those with neurological diseases such as multiple sclerosis or Parkinson's, or for people who had a stroke.

15 Oct 2009

More than half RCTs do not report vital information about study populations race, says study

A new study recently published online by the American Heart Journal shows that more than half of all randomized clinical trials, or RCTs, for cardiovascular disease are not reporting vital information about the study populations race or ethnicity. NYU School of Medicine researchers found that out of the 156 cardiovascular disease RCTs analyzed, only 35% of trials reported any information on race or ethnicity between 1970 and 2006. From 2000 to 2006, 46% of trials included that information.

15 Oct 2009

Jazz Pharmaceuticals to present Phase III sodium oxybate trial data at ACR 2009 meetings

Jazz Pharmaceuticals, Inc. announced that data from the company's first Phase III clinical trial of sodium oxybate (JZP-6) for the treatment of fibromyalgia will be presented during the American College of Rheumatology 2009 Annual Meeting (ACR) in Philadelphia, Pennsylvania and also in November during the US Psychiatric and Mental Health Congress (US Psych Congress) in Las Vegas, Nevada.

15 Oct 2009

Positive data from Cardium Therapeutics' Matrix Phase 2b Excellarate trial

Cardium Therapeutics today reported positive data from its Matrix Phase 2b clinical trial of Excellarate(TM) for the potential treatment of patients with chronic non-healing diabetic foot ulcers based on the Company's Gene Activated Matrix (GAM) technology platform.

15 Oct 2009

ValenTx to present its first clinical study for the treatment of morbid obesity

ValenTx, Inc. announces the presentation of the first clinical study of their endoluminal approach for the treatment of morbid obesity at the 2009 American College of Surgeons Clinical Congress.

15 Oct 2009

NIH awards grant to conduct genetic drug research on cancer and heart disease

A Virginia Tech chemist has been awarded a $2.3 million grant from the National Institutes of Health (NIH) to conduct research that will aid in the development of new heart disease and cancer medicines that have fewer side effects.

15 Oct 2009

FDA approves ZyStor Therapeutics' ZC-701 for Phase I human safety trial

ZyStor Therapeutics, Inc., a biotechnology company developing a new class of targeted protein therapeutics for the treatment of Lysosomal Storage Diseases using the Company's proprietary Glycosylation Independent Lysosomal Targeting technology, today announced that it has received clearance from the U. S. Food and Drug Administration to proceed into a clinical trial for its first drug candidate, ZC-701, an enzyme replacement therapy for the treatment of Pompe disease.

14 Oct 2009

Positive data from ZIOPHARM's palifosfamide sarcoma Phase II trial

ZIOPHARM Oncology, Inc. announced today positive top line interim data from the multicenter randomized Phase II trial of palifosfamide (ZymafosTM, ZIO-201) treating patients with unresectable or metastatic soft tissue sarcoma. The analysis evaluated 62 patients treated as of the end of September, with 58 being analyzed.

14 Oct 2009

EMEA grants ArQule's ARQ 197 orphan drug designation

ArQule, Inc. today announced that the European Medicines Evaluation Agency (EMEA) has designated ARQ 197 as an orphan medical product for the treatment of soft tissue sarcoma.

14 Oct 2009

Vision scientists identify an intricate process that allows the human eye to adapt quickly to darkness

Ever wonder how your eyes adjust during a blackout? When we go from light to near total darkness, cells in the retina must quickly adjust. Vision scientists at Washington University School of Medicine in St. Louis have identified an intricate process that allows the human eye to adapt to darkness very quickly. The same process also allows the eye to function in bright light.

14 Oct 2009

Medical Condition News

MSU receives $6.2 million Morris K. Udall Center of Excellence for Parkinson's disease grant

Gelotophobia has no cultural barriers

Foundation for Chiropractic Progress joins 92 national associations in support of World Spine Day

Diet and exercise program unlikely to eliminate OSA in overweight patients

Shortage of general surgeons may be linked to higher rate of perforated appendix in rural areas

Marker genes help determine the effectiveness of targeted molecular drug regimen for treating GIST

NYU Langone Medical Center to establish a schizophrenia research center with $10M NIMH grant

Much remains to be done for autism spectrum disorders, say experts

Genetic mutation implicated in breast and ovarian cancers could also have a role in causing heart failure: Study

Curemark commences enrollment in Phase III CM-AT clinical trials for autism treatment

Control and coordination may aid multiple sclerosis patients perform daily activities independently

More than half RCTs do not report vital information about study populations race, says study

Jazz Pharmaceuticals to present Phase III sodium oxybate trial data at ACR 2009 meetings

Positive data from Cardium Therapeutics' Matrix Phase 2b Excellarate trial

ValenTx to present its first clinical study for the treatment of morbid obesity

NIH awards grant to conduct genetic drug research on cancer and heart disease

FDA approves ZyStor Therapeutics' ZC-701 for Phase I human safety trial

Positive data from ZIOPHARM's palifosfamide sarcoma Phase II trial

EMEA grants ArQule's ARQ 197 orphan drug designation

Vision scientists identify an intricate process that allows the human eye to adapt quickly to darkness

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Latest News